BRIGHTWAY
4.11.2021 18:07:09 CET | Business Wire | Press release
SUZHOU BRIGHTWAY released the latest flagship Electric Scooter NAVEE N65 on Xiaomi Youpin crowdfunding website, and raised more than €430,000 successfully.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104006077/en/
BRIGHTWAY has a professional design and R&D team with rich experience in micro-mobility. Based on the thorough understanding of customers’ requirements and pain points, as well as the full consideration of practicality, safety and comfort at the stage of design, BRIGHTWAY team finally launched NAVEE N65 with the following key features, making the N65 perfect and the most suitable for commute or joy ride.
65KM Ultra-long Range : Travelling up to 65 km on a single charge, the N65 can make the charging frequency from one time per day to one time per week for the customers with short distance commuting within 10km.
10 Inch Big Tires: In order to deliver extremely comfortable and smooth riding experience for riders, the N65 is equipped 10-inch big off-road pneumatic tires.
Rated Power 500watt Brushless Motor: It improves the climbing performance up to 25%, and supports three different speed level (1st level to 15km/h, 2nd level to 25km/h, 3rd level to 32km/h). The maximum speed can reach 32 km/h. (Noted: The maximum speed varies according to the laws and regulations of different regions, please refer to the requirements of the laws and regulations)
Double Rotation Folding System: With innovative design of folding neck and handlebar, the N65 makes the pre-assembling and folding more convenient.
Features:
- Ultra-long range up to 65 km;
- Innovative design of double rotation folding system;
- 25% superb uphill climbing ability;
- 10 inch off-road pneumatic tires;
- Rated power 500watt brushless motor;
- Max loading weight 120kg;
- 17cm wide magnesium alloy deck;
- Front E-ABS brake with rear disc brake;
- Separated big HMI;
- Three speed levels;
- Support cruise control and energy recovery with APP.
- Ultra-bright front light
In middle November, NAVEE N65 will be launched at European market with only priced at €649. And the limited-time promotion price is just €599.
About BRIGHTWAY
SUZHOU BRIGHTWAY Intelligent Technology Co., Ltd is an innovative high-tech enterprise focusing on R&D, production and distribution of E-scooters and E-bikes. Equipped with advanced technology and strong R&D strength, SUZHOU BRIGHTWAY Intelligent Technology Co., Ltd. now is also an emerging Xiaomi ecological chain company.
For more information, please visit http://navee-tech.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom